医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

InnoCare Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China

2022年06月22日 PM12:37
このエントリーをはてなブックマークに追加


 

BEIJING

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in clinical trial of the Company’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189 in China.

ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed for the treatment of solid tumors as a single agent and/or in combination with other antitumor agents.

SHP2 is involved in mediating MAPK signaling pathway and immune checkpoint pathway for the regulation of cellular proliferation and survival. Preclinical studies have shown that ICP-189 has excellent selectivity over other phosphatases and demonstrated significant anti-tumor effects in various xenograft models.

Dr. Jasmine Cui, Co-Founder, Chairwoman and CEO of InnoCare, said, “ICP-189 has entered into clinical stage in China and the U.S. SHP2 inhibitor has high potential for targeting a variety of solid tumors. We will push forward the clinical development of ICP-189 to provide treatment options for patients in China and around the world.”

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on liquid cancer, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220621006171/en/

CONTACT

Media

Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investor Relations

86-10-66609999

ir@innocarepharma.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • ウォルグリーン・ブーツ・アライアンスが戦略的見直しを完了し、好業績のブーツ事業の所有権を保持することを決定
  • OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial
  • DEXLEVO Strengthens Global Reputation of GOURI at IMCAS, the World’s Largest Beauty Anti-Aging Society
  • Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
  • Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years